在多发性骨髓瘤患者和健康人群中,F158V等位基因的频率不同
Michaël Constantinides1,2, Nicolas Robert3, Caroline Multrier1
1IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, France.
Oncoimmunology
|August 23, 2024
概括
FCGR3A-158F/F基因型与多发性骨髓瘤和MGUS患者的免疫细胞变化有关. 这种FCGR3A多态可能会影响瘤血细胞的发育,但不会影响治疗反应.
科学领域:
- 免疫遗传学 免疫遗传学
- 血液学 血液学 血液学
- 在瘤学瘤学.
背景情况:
- FCGR3A基因在位置158 (V/F) 具有单个核酸多态,影响抗体片段结晶 (Fc) 结合.
- FcγRIIIa-158 V全型表现出更高的亲和力,并且与IgG1单克隆抗体 (mAb) 治疗中改善的临床结果相关.
研究的目的:
- 在患有B细胞淋巴增殖性疾病的患者中研究FCGR3A-F158V多态的等位基频率.
- 检查FCGR3A-158基因型与多发性骨髓瘤 (MM) 中的免疫微环境变化之间的关联.
主要方法:
- 在患者队列 (MM,MGUS,NHL,B-CLL) 中对FCGR3A-F158V等位基因频率进行比较分析.
- 免疫细胞群 (T细胞,巨细胞,NK细胞) 的流细胞计评估在骨髓中,由FCGR3A基因型分层的MM患者.
主要成果:
- 在MM和MGUS患者中,FCGR3A-158F同卵性基因型得到了丰富,但在B-CLL或NHL中没有.
- 患有F/F基因型的MM患者显示CD8T细胞和静止记忆CD4T细胞减少,巨细胞增加.
- 相反,自然杀手 (NK) 细胞数量在V/V同卵性个体中升高.
- 根据FCGR3A基因型,没有观察到化学疗法+/-达拉图巴治疗反应的显著差异.
结论:
- FCGR3A F158V多态影响免疫微环境,可能影响MM的瘤血细胞发育.
- 尽管有免疫失调,但FCGR3A基因型在本研究中并没有影响对含达拉图马布的治疗方案的临床反应.
相关概念视频
02:26Comparing Copy Number Variations and SNPs
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:30Point and Frameshift Mutations
Point mutations are genetic alterations involving the change of a single nucleotide base pair in DNA. Depending on how the alteration affects protein synthesis, they can lead to various consequences.Point mutations fall into the following types:Silent mutations occur when a nucleotide change does not alter the amino acid sequence due to the redundancy of the genetic code. For instance, changing ACC to ACA still encodes threonine, leaving the protein function unaffected. This occurs because...